Back

Biomarker Convert: a novel approach to transform plasma pTau217 results across immunoassay and mass spectrometry analytical platforms

Quadrini, K. J.; Aubrecht, J.; Vernhes, F.; Zeng, X.; Johnson, A. D.; Snitz, B. E.; Cohen, A. D.; Tooker, R.; Quiceno, M. E.; Campbell, B. M.; Karikari, T. K.; Swanson, C. J.

2026-10-01 neurology
10.64898/2026.09.28.26363900 medRxiv
Show abstract

INTRODUCTION: We report the development and validation of a novel computational tool to cross-convert plasma pTau217 results from different assays to facilitate recruitment for therapeutic trials and observational studies. METHODS: Participants underwent A{beta} PET imaging and plasma pTau217 measurement on up to three assay platforms across three cohorts. We then developed conversion equations using Deming regression -- collectively named Biomarker Convert -- and evaluated robustness using independent research cohorts. Finally, we modeled the potential impact of pTau217 screening on trial enrollment. RESULTS: While absolute plasma pTau217 concentrations differed, the assays had similar predictive characteristics for A{beta} positivity (LC-MS/MS [C2N], AUC=0.952; Janssen Simoa, AUC=0.946; Lumipulse, AUC=0.929). Biomarker Convert enabled transformation of plasma pTau217 data across assays independent of A{beta} PET and clinical status. Plasma pTau217 reduced A{beta} PET scans in the model screening paradigm by >60%. DISCUSSION: Biomarker Convert equations enable harmonization of plasma pTau217 values from immunoassay and mass spectrometry platforms, supporting direct data comparison.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.